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Abstract
Background: Tumor-associated macrophages (TAMs) remodel the colorectal cancer (CRC) microenvironment. Yet, findings
on the role of TAMs in CRC seem to be contradictory compared with other cancers. FoxP3
+ regulatory T (Treg)-cells
dominantly infiltrate CRC. However, the underlying molecular mechanism in which TAMs may contribute to the trafficking
of Treg-cells to the tumor mass remains unknown.
Methodology/Principal Findings: CRC was either induced by N-methyl-N-nitrosourea (MNU) and H. pylori or established by
subcutaneous injection of mouse colorectal tumor cell line (CMT93) in mice. CMT93 cells were co-cultured with primary
macrophages in a transwell apparatus. Recruitment of FoxP3 green fluorescence protein positive (FoxP3
GFP+) Treg-cells was
assessed using the IVIS Imaging System or immunofluorescence staining. A role for macrophages in trafficking of Treg-cells
and in the development of CRC was investigated in CD11b diphtheria toxin receptor (CD11b-DTR) transgenic C57BL/6J mice
in which macrophages can be selectively depleted. Treg-cells remarkably infiltrated solid tumor, and predominantly
expressed the homing chemokine receptor (CCR) 6 in the induced CRC model. Both CMT93 cancer cells and macrophages
produced a large amount of CCL20, the sole ligand of CCR6 in vitro and in vivo. Injection of recombinant mouse CCL20 into
tumor sites promoted its development with a marked recruitment of Treg-cells in the graft CRC model. Conditional
macrophage ablation decreased CCL20 levels, blocked Treg-cell recruitment and inhibited tumor growth in CD11b-DTR
mice grafted with CMT93.
Conclusions/Significance: TAMs recruit CCR6
+ Treg-cells to tumor mass and promote its development via enhancing the
production of CCL20 in a CRC mouse model.
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Introduction
Colorectal cancer (CRC) is one of the most common cancers
worldwide, and the fourth most common cause of cancer-
associated death [1]. Similar to other types of cancer, CRC arises
in chronically inflamed tissue, and its development is under
immune surveillance and depends on cytokines and chemokines
secreted from tumor-infiltrating immune cells [2].
Regulatory T (Treg)-cells were initially characterized by their
CD4
+CD25
+FoxP3
+ phenotype and are thought to balance
necessary aggressiveness against foes with tolerance for self-
constituents [3]. Increased numbers of Treg-cells have been
reported in the blood and tumors of patients with various cancers,
including breast cancer, colorectal cancer, esophageal cancer,
gastric cancer, hepatocellular carcinoma, leukemia, lung cancer,
lymphoma, melanoma, ovarian cancer, and pancreatic cancer [4].
Moreover, studies that depleted Treg-cells resulted in improved
antitumor immunity and markedly reduced tumor growth in
several mouse tumor models [4]. In patients with CRC, an
increased numbers of Treg-cells in peripheral blood, mesenteric
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Moreover, antibody-mediated FoxP3 protein therapy resulted in a
clinically significant reduction in tumor burden in a syngeneic
model of colon cancer metastasis to liver in Balb/c mice [7].
Knowledge regarding the origin of Treg-cells accumulating
inside tumor lesions comes from animal tumor model studies. It
has been proposed that both pre-existing naturally occurring Treg-
cells (nTreg-cells) and adaptive Treg-cells (aTreg-cells) induced
from non-Treg precursor cells contribute to the total pool of
tumor-infiltrating FoxP3
+ Treg-cells [8,9]. Intratumoral Treg-cells
are antigen experienced, highly activated and appear to undergo
extensive cellular proliferation as the majority of intratumoral
Treg-cells have lost CD62L and CD45RB expression, but their
expression of CD25, CTLA-4 and GITR is strongly increased
[8,10]. The depletion of pre-existing nTreg-cells using anti-CD25
mAb resulted in more rapid and extensive conversion of precursor
cells to aTreg-cells, which can largely compensate for the loss of
nTreg-cells [8]. The activation and expansion of either nTreg-cells
or aTreg-cells at tumor sites is antigen dependent, and contributes
to the tumor specific tolerance [4]. In particular, antigen
presenting cells such as tumor-infiltrating DCs and macrophages
are likely involved in the local activation and expansion of nTreg-
cells inside tumor lesions [11]. Moreover, in humans, tumor
antigen specific FoxP3
+ Treg-cells have been successfully isolated
from tumor tissues as well as peripheral blood of patients with
melanoma and cervical cancer [12,13].
FoxP3
+ Treg-cells begin to infiltrate into the incipient tumor
lesion at a very early stage of tumor development [14]. Studies
with human ovarian cancers have shown that Treg-cells traffick to
the tumor mass and ascites via chemokine receptor CCR4
responding to CCL22 released by tumor cells and tumor-
associated macrophages (TAMs). This suggests that chemokine
and chemokine receptors are important for Treg-cell homing to
tumours [15]. However, other chemokine receptors, for example,
CXCR3, and CCR6, which are shared with memory Th1, Th2
and Th17 cells, have also been shown to be expressed by tumor-
infiltrating Treg-cells [16,17]. CCR6 is a chemokine receptor with
only one single known specific chemokine ligand, the inflamma-
tory and homeostatic chemokine CCL20 which is also known as
liver and activation-regulated chemokine (LARC) [18] or Exodus
[19]. In contrast to many other chemokines, CCL20 has a
relatively specific receptor and binds almost exclusively to the
chemokine receptor CCR6, which is also expressed by CD45RO
+
memory T cells and others [20].
Despite the fact that tumor development could be promoted in
part by the immune system itself, the suppressive function of Treg-
cells, as well as the molecular mechanism underlying their
trafficking to tumor sites remains elusive. In this study, we
investigated the homing characteristics of Treg-cells, and the
potential tumor-promoting function of TAMs in a CRC model.
We report that, in solid tumors of mice with CRC, Treg-cells were
significantly increased compared to control groups. TAMs
contributed to the increased CCL20 production in the tumor
environment and recruited Treg-cells that expressed high levels of
CCR6. Injection of recombinant mouse CCL20 into CRC
promoted tumor development with a marked recruitment of
Treg-cells in wild-type mice, and stimulated tumor growth by
directly activating CMT93 cells in CCR62/2 mice. Most
importantly, using CD11b-DTR transgenic mouse model we
demonstrate for the first time that conditional macrophage
ablation not only decreased expression of CCL20 and FoxP3
but resulted in a significant inhibition of CRC. Our data suggest
that selectively targeting CCL20 by down-regulating the activity of
TAMs or its counter receptor CCR6 to block memory Treg-cell
recruitment may represent a novel therapeutic strategy against
CRC in humans.
Results
Numbers of FoxP3
+ Treg-cells were increased in tumor-
infiltrating lymphocytes of CRC in mice
A major goal of the present study was to provide a definitive
demonstration of the trafficking mechanism for FoxP3
+ Treg-cells
in CRC in vivo. To this end, we induced CRC in mice with MNU
and H. pylori. MNU is a direct alkylating agent that does not
require metabolic activation and thus is a potent topical
carcinogen [21]. Previously, intrarectal instillation of MNU has
been reported to induce CRC in rats [21]. As expected, after 80
weeks, 85% mice used in this study developed visible CRC
induced by MNU and H. pylori (Figure 1A–C). H&E staining
further showed scattered tumor cells in sections derived from CRC
in mice (Figure 1D, E). These data clearly suggest that the
method used in this study represents an effective strategy for the
induction of CRC in mice.
To investigate whether FoxP3
+ Treg-cells were infiltrating tumors
induced by MNU and H. pylori in mice, immunofluorescence
stainingofthe tumorand normalcolonforFoxP3wasperformed.As
observed in PBMC of human patients (Figure S1), FoxP3 (Red
staining) was abundantly expressed in tumor tissue derived from
mice treated with MNU and H. pylori compared with normal colon
of untreated mice or IgG control staining (Figure 1F–H). To look
more precisely at the frequency of Treg-cells infiltrating the CRC,
single cell suspension of CRC and normal mucosa was prepared and
the frequency of Treg-cells was determined by Flow cytomery. We
confirmed that a significantly higher frequency of CD4
+FoxP3
+
Treg-cells were present in the tumor, as compared to normal colon
(mean 9.095%61.038% vs mean 0.478%60.095%, p,0.0001)
(Figure 1I–K). The increased density of Treg-cells in tumor-
infiltrating lymphocytes (TIL) strongly suggests that Treg-cells may
play an essential role in modulating anti-tumor immune responses in
the mouse model of CRC induced by MNU and H. pylori.
CCR6 was required for recruitment of Treg-cells to CRC in
mice
To address the question of whether naturally occurring FoxP3
+
Treg-cells are able to migrate to tumor tissues after adoptive
transfer, we injected 0.5–1610
6 Treg-cells that were isolated from
FoxP3
GFP transgenic mouse in to mice bearing CRC induced by
MNU and H. pylori or healthy controls. Two weeks post adoptive
transfer, cryosections derived from tumor tissue of mice injected
with FoxP3
GFP+ cells were examined for GFP
+ Treg-cells. We
observed that GFP
+ Treg-cells massively accumulated within the
tumor (Figure 2A). Notably, we identified that these accumulat-
ing GFP
+ Treg-cells within colorectal tumor expressed CCR6, the
Treg-cell homing receptor (Figure 2B). However, naı ¨ve Treg-
cells derived from FoxP3
GFP transgenic mice did not express
CCR6 (Figure 2C–D). In addition, we digested colorectal tumor
from mice treated with MNU and H. pylori, and determined
CCR6 expression of tumor-infiltrating Treg-cells by Flow
cytomery. Consistently, we found tumor-infiltrating Treg-cells
almost exclusively expressed CCR6 (Figure 2E, F). In order to
confirm whether CCR6 was required for migration of Treg-cells to
tumor sites, we grafted mouse colorectal tumor cell line CMT93
into CCR6 2/2 mice. Two weeks after CMT93 grafting, tumor-
infiltrating Treg-cells in CCR6 2/2 mice were examined by Flow
cytomery. We observed that the infiltration of Treg-cells was
completely prevented in the absence of CCR6 in CCR6 2/2
mice compared with CCR6 +/+ mice (Figure 2G, H). These
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Treg-cells to the tumor mass is dependent on the chemokine
receptor CCR6 in vivo in the CRC mouse model grafted with
CMT93.
TAMs contributed to the production of CCL20, the ligand
of CCR6
CCL20 is so far known to be the only ligand for CCR6 and
capable of directing the migration of CCR6
+ cells [20]. To
examine the possible production of CCL20 in tumor tissue, tumor
cryosections taken from C57BL/6J mice treated with MNU and
H. pylori were immunostained with anti-mouse CCL20 mAb. We
observed that expression of the chemokine CCL20 (red staining)
was markedly increased in CRC tissues compared with normal
mucosa (Figure 3A, B). Coordinated signaling between tumor
cells and nonmalignant inflammatory cells in the tumor microen-
vironment is required for the development of tumors. Among
them, macrophages are major producers of proinflammatory
cytokines such as tumor necrosis factor-a (TNF-a), IL-1b, and IL-
6, and play a crucial role in modulating immune responses [22]. In
order to investigate whether macrophages are an important source
of CCL20 in the tumor sites, double immunofluorescence staining
was performed on cryo-sections derived from tumor biopsies of
mice treated with MNU and H. pylori. We observed that in
addition to F4/80
+ macrophages, other cells also produced
CCL20 in the tumor sites of mice (Figure 3C), indicating that
CCL20 released by TAMs or others may induce Treg-cell
migration to tumors. To clarify what other cells produce
CCL20, we transducted CMT93 with GFP, and grafted
subcutaneously to C57BL/6J mice (Figure 3D). Three weeks
later, we detected the majority of CCL20
+ cells (78.98%) was
GFP
+ CMT93 tumor cells, suggesting most of other CCL20
producing cells are tumor cells (Figure 3E). To determine
whether macrophages are responsible for the overproduction of
CCL20 in the tumor mass, we co-cultured CMT93 cancer cells
with fresh mouse peritoneal macrophages for 48 hrs in a transwell
apparatus. We demonstrated that in the co-culture both
macrophages and CMT93 cancer cells produced increased levels
of CCL20 compared with either macrophages or CMT93 culture
alone (Figure 3F, G). Strikingly, in the co-culture of CMT93 and
mouse peritoneal macrophages, CMT93 cancer cells produced
26.4-fold more CCL20 than macrophages at mRNA levels,
suggesting that macrophages may interplay with cancer cells for
production of CCL20 in the tumor microenvironment
(Figure 3F). In addition, increased protein levels of CCL20 were
confirmed by ELISA in the co-culture (Figure 3H).
Simultaneous injection of recombinant mouse CCL20
results in the trafficking of CCR6
+ Treg-cells into tumors,
and promotion of CRC growth in mice
Tumor-infiltrating Treg-cells suppress the priming and effector
function of tumor killing effector T cells, contributing to tumor
growth and development [11]. To determine the role of CCL20 in
the migration of Treg-cells in vivo, we s.c. injected CMT93 murine
CRC cells together with recombinant mouse CCL20 into
FoxP3
GFP transgenic mice. Using the whole-body small animal
fluorescence imaging system to monitor the migration of Treg-cells
[23], we demonstrated that recombinant mouse CCL20 recruited
a large number of GFP
+ Treg-cells into tumors (white arrow)
compared to PBS treated groups (Figure 4A–C). In order to
further confirm GFP labeled Treg-cells migrated to the tumor
mass in response to recombinant mouse CCL20, single cell
suspensions of tumor tissue were prepared and FoxP3
GFP+ Treg-
cells were detected by Flow cytomery at the end of the experiment.
In contrast to PBS treatment, we observed that GFP
+ Treg-cells
were significantly increased within the tumor that was treated with
recombinant mouse CCL20 (Figure 4D). To further study the
pathological importance of CCL20, we administrated recombi-
nant mouse CCL20 around tumor sites weekly for 4 weeks. We
showed that tumor size was significantly increased in mice treated
with recombinant mouse CCL20 compared with PBS controls
(Figure 4E), suggesting a critical role of CCL20 in CRC growth
and development. In human CRC patients, CCR6 was also found
to be expressed by primary CRC cells [24]. Therefore, for the
definitive confirmatory study, we grafted CMT93 CRC cancer
cells into CCR62/2 mice. In this model, tumor-infiltrating
lymphocytes (TIL) will not express CCR6. Two weeks later we
analyzed by Flow cytometry for CCR6 expression of single cell
suspension prepared from graft CRC. Consistent with study in
human CRC patients [24], we noted that in CCR62/2 mice, as
much as 73.71% of graft CRC cells expressed CCR6 (Figure 4F).
Most interestingly, we observed that recombinant mouse CCL20
stimulated CMT93 CRC cell growth by directly activating CCR6
on tumor cells in the absence of CCR6
+ TIL in CCR62/2 mice
(Figure 4G). This CCL20 mediated effect is likely to occur via
attracting Treg-cells to the tumor mass or directly stimulating
CRC cancer cells or both.
Selective depletion of macrophages in CD11b-DTR mice
decreased CCL20 tumor levels, blocked CCR6
+ Treg-cell
recruitment into the tumor mass and inhibited tumor
growth
CD11b-DTR transgenic mice have CD11b promoter-mediated
expression of the human diphtheria toxin (DT) receptor, and this
inducible system selectively depletes macrophages in vivo when DT
is injected [25]. To examine whether in vivo DT treatment could
eliminate TAMs in CMT93 graft CRC model, we first injected
DT or DT
mu at a concentration of 25 ng/g mouse weight one day
prior to grafting CMT93 in CD11b-DTR transgenic mice.
Thereafter, we treated mice with DT or DT
mu at a concentration
of 5 ng/g every three days for 14 days. In agreement with others,
we demonstrated that DT selectively depleted F4/80
+ macro-
phages 24 h after injection, but had no significant effect on T cells,
neutrophils, mast cells or mature Langerhans cells/dendritic cells
Figure 1. Increased numbers of FoxP3
+ Treg-cells in tumor-infiltrating lymphocytes of CRC induced by MNU and H. pylori. in mice.
(A) Eighty weeks old C57BL/6J mouse with large CRC induced by MNU and H. pylori.( B) Higher magnification of the area indicated by the triangle (D)
of (A). (C) Transect of the area indicated by the asterisk (*) of (B). (D) H&E staining of colorectal carcinoma tissue derived from CRC induced by MNU
and H. pylori (original magnification, 620). (E) Higher magnification of (D) as indicated by the rectangle. To examine FoxP3
+ Treg-cells in mice with
CRC induced by MNU and H. pylori, immunofluorescence staining of FoxP3 was performed on cryosections from mouse CRC or normal colon tissue.
(F) Expression of FoxP3 (Red staining) in mouse CRC (original magnification,620,640 and6100). (G) Negative expression of FoxP3 in mouse colon
tissue (original magnification, 620). (H) Rat IgG control staining (original magnification, 620). Lymphocytes infiltrating CRC (n=10) and normal
mucosa (n=6) were isolated for Flow cytometric analysis of FoxP3 expression. (I, J) The frequency of Treg-cells in CRC derived from eighty weeks old
C57BL/6J mouse and normal mucosa in mice. (K) A significant increase in the frequency of Treg-cells was found in TIL of CRC compared with normal
mucosa (p,0.0001 by Student’s t Test). Representative data are shown which had been reproduced in 3 independent experiments.
doi:10.1371/journal.pone.0019495.g001
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revealedthat DTtreatmentcompletelyeliminatedF4/80
+TAMsin
CRC compared with DT
mu injection (Figure 5A, B). We further
examined CCL20 expression in tumor tissue derived from mice
treated with DT, we found that selective depletion of macrophages
resulted into a marked decrease in both CCL20 mRNA level
(Figure 5C) and CCL20 protein level (Figure 5D) in tumor mass
compared with DT
mu treatment. To investigate whether TAMs
promote the release of CCL20 from CMT93 tumor cells in vivo,w e
grafted GFP
+ CMT93 tumor cells in CD11b-DTR transgenic mice.
After treatment of DT or DT
mu for 14 days, we observed that the
selective depletion of TAMs evidently inhibited the production of
CCL20 by CMT93
GFP mouse tumor cells, suggesting that TAMs
are not only the major source of CCL20 but also distinctly
contribute to the release of CCL20 from CRC cells in mice
(Figure 5E). Furthermore,wedemonstrated that DTtreatmentdid
not decrease CCR6 expression by CMT93
GFP mouse tumor cells in
comparisontoDT
mu(Figure5F).However,mouseCRCcellshave
low CCR6 expression before grafting to hosts (Figure 5F). Most
importantly, macrophage depletion by administration of DT led to
a marked reduction in the number of tumor-infiltrating FoxP3
+
Treg-cells (Figure 5G, H). Together, these data indicate that
TAMssupporttheaccumulationofCCR6
+tumor-infiltratingTreg-
cells, and, at least in part via this mechanism, promote the release of
CCL20 inCRCinmice. Finally, we found that selective elimination
of TAMs dramatically inhibited the growth of CRC in mice
(Figure 5I, J), demonstrating a critical tumor-promoting role of
TAMs in CRC mouse model.
Discussion
The innate and adaptive immune systems can promote tumor
development through inflammation-dependent mechanisms
[2,27]. This event is coordinated by many inflammatory cells,
among them FoxP3
+ Treg-cells are thought to suppress T cell
immunity to tumor-associated antigens and to facilitate tumor
progression [4]. FoxP3 is the most definitive maker of Treg-cells,
and its detection could allow a better understanding of the
mechanisms through which Treg-cells are involved in autoim-
mune and infectious diseases, as well as transplantation and tumor
immunity [28]. Although many studies have focused on the role of
Treg-cells in controlling self-reactivity, there is a growing body of
evidence indicating that Treg-cells have a significant impact on the
host response to cancer [29,30], including CRC [31,32]. It was
previously reported that patients with high frequencies of
infiltrating CD3
+ T cells within their colorectal tumors have been
thought to have a better 5-year survival rate (73%) than those with
low levels of CD3
+ T cells (30%) [33]. However, within this CD3
+
T cell population, apart from effector T cells, Treg-cells are
considered to suppress anti-tumor immune responses in patients
with CRC [34]. In this study we have also confirmed that FoxP3
+
Treg-cells are highly accumulated in the microenvironment in
CRC mouse model, supporting the notion that the presence of
Treg-cells may allow the escape of tumor cells from immune
surveillance by cytotoxic T lymphocytes in CRC patients.
Like other human diseases, mouse models are widely used to
elucidate mechanisms involved in colon carcinogenesis (initiation,
promotion and progression) as well as studies on chemoprevention
and intervention [35]. Herein, we induced CRC in C57BL/6J
mice with MNU and H. pylori to investigate Treg-cell trafficking,
differentiation and function. MNU is a direct alkylating agent that
does not require metabolic activation and thus is a potent topical
carcinogens [21]. We have found the strategy used for the
induction of CRC in mice is quite effective as 85% mice used in
this study developed visible CRC under the challenge of MNU
and H. pylori (unpublished observations).
Evidence supporting an essential role for FoxP3
+ Treg-cells in
tumor immune evasion comes from studies that eliminated Treg-
cells before tumor challenge. This treatment resulted in tumor
rejection in several mouse tumor models [10,36,37,38]. As in
human settings [34], an increased numbers of Treg-cells were
observed both in peripheral blood (Figure S2) and solid tumors in
mice treated with MNU and H. pylori compared with normal colon
of untreated mice. Most interestingly, in solid tumors derived from
mice treated MNU and H. pylori, the frequency of CD4
+FoxP3
+
Treg-cells was an average of 9.095% of the total TIL, suggesting
that these accumulated Treg-cells may serve as a common
immune evasion mechanism to impede immunosurveillance
against autologous tumor cells. Treg-cells perform an important
function to limit autoimmunity and so targeting Treg-cell
migration may serve as a novel and preferred approach in the
immunotherapy of overall tumor progression. Additionally, we
have detected some CD4
2 cells expressing FoxP3 in the tumor
mass. The origin of CD4
2FoxP3
+ cells will be submitted to the
future investigation.
To function effectively in the tumor microenvironment, Treg-
cells must migrate to and operate in various lymphoid and non-
lymphoid organs. Similar to effector T cell populations, Treg-cell
populations are subdivided on the basis of their expression of
homing receptors into subsets that are predicted to migrate
preferentially to certain tissues [39]. Studies with human ovarian
cancers have revealed that Treg-cells home to the tumor mass and
ascites via CCR4 in response to tumor cell- and TAM-derived
CCL22 [15]. Yet, emerging evidence has suggested that apart
from CCR4 some other chemokine receptors are involved in
guiding Treg-cell trafficking in different types of tumors in both
human and mice [17,40]. Therefore, chemokine receptor
expression patterns appear to be highly heterogeneous within
the peripheral FoxP3
+ Treg-cell population [11]. To date, no
single homing receptor has been identified that is specifically
expressed by Treg-cells. However, among CD4
+ T cells, the
chemokine receptor CCR6 is mainly expressed by Treg-cells in
various inflammatory settings [41]. Similarly, the CCR6 ligand
CCL20 is constitutively expressed by intestinal epithelial cells, and
upregulated in epithelial cells during inflammation [42]. Consis-
tent with this concept, our data demonstrated that naı ¨ve Treg-cells
derived from FoxP3
GFP mice do not express CCR6, while
FoxP3
GFP+ Treg-cells predominantly expressed high levels of
CCR6 in tumor tissue 2 weeks after adoptive transfer into tumor
bearing mice. Our data provide strong evidence that these CCR6
+
Figure 2. Requirement of CCR6 for trafficking of Treg-cells to CRC in mice. Treg-cells (0.5–1610
6) purified from spleens of FoxP3
GFP mice
were adoptively transferred into mice bearing CRC induced by MNU and H. pylori.( A) Cryosections from tumor were stained for cell nuclei with DAPI
to investigate infiltration of FoxP3
GFP+ Treg-cells in tumor mass (original magnification, 620). (B) Co-localization of GFP with CCR6 staining. (C, D)
Flow cytometric analysis for CCR6 of FoxP
GFP+ Treg-cells derived from peripheral blood of naı ¨ve FoxP3
GFP mice. (E, F) Flow cytometric analysis for
CCR6 of infiltrating Treg-cells derived from CRC induced by MNU and H. pylori in mice. To confirm whether CCR6 is required for FoxP3
+ Treg-cell
trafficking, CMT93 cell line was grafted into CCR62/2 and CCR6+/+ mice. (G, H) Flow cytometric analysis of tumor-infiltrating CD4
+FoxP3
+ Treg-cells
two weeks after CMT93 cell line grafting in CCR62/2 (G) and CCR6+/+ (H) mice. Representative data are shown which had been reproduced in 4
independent experiments.
doi:10.1371/journal.pone.0019495.g002
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PLoS ONE | www.plosone.org 7 April 2011 | Volume 6 | Issue 4 | e19495Treg-cells exhibit a prevalent memory phenotype, and clearly they
might be tumor antigen experienced.
We have demonstrated a critical role of CCL20 in the
recruitment of Treg-cells into tumor tissue by the injection
recombinant mouse CCL20. The administration of recombinant
mouse CCL20 resulted in a marked accumulation of CCR6
+
Treg-cells in tumor sites as detected by both immunofluorescence
staining and an in vivo fluorescence imaging. Most importantly, our
finding revealed that the administration of recombinant mouse
CCL20 led to a marked increase in tumor size in our CRC mouse
model. Previous studies evaluating CCR6 expression levels by
immunohistology in 64 CRC primary tumor specimens found that
CCR6 staining was significantly stronger in cancer cells compared
with adjacent colon epithelial cells [24]. In CCR62/2 mice
grafted with CMT93, we convincingly showed that aside from
TIL, 73.71% of CRC cells expressed CCR6. Using GFP labeled
CMT93, we demonstrated that besides macrophages the majority
of CCL20 producing cells in the tumor microenvironment were
cancer cells. In this study, besides tumor-infiltrating CCR6
+ Treg-
cells we have confirmed the direct contribution of CCR6
expressed by CMT93 CRC cells to the CRC growth and
development in CCR62/2 mice, the clinical application of
targeting the CCR6-CCL20 chemokine axis may harbor thera-
peutic potential for the treatment of patients with CRC. However,
our preliminary data indicated that the reconstitution of 10610
6
CD3
+ T cells derived from FoxP3 knock-out mice (no FoxP3
+
Treg-cells) resulted in a decrease in size of CRC in CCR62/2
mice compared with CD3
+ T cells derived from wild type mice
(unpublished observation), hints to promoting effect of CCR6
+
Treg-cells in the development of CRC in mice.
Ablation of macrophage function, or inhibition of their
infiltration into experimental tumors, inhibits growth and
metastases, strongly suggests that macrophages are involved in
promoting tumor progression [43]. The gastrointestinal mucosa is
the largest reservoir of macrophages in the body. These important
effector cells are derived from blood monocytes that are recruited
to the lamina propria by inflammatory chemokines and bacterial
products during inflammation [44]. Rectal tumors are usually
infiltrated by TAMs and it is widely accepted that TAMs in
various tumor tissues assist tumor growth by producing various
growth factors and proangiogenic cytokines. The tumor environ-
ment is thought to ‘educate’ macrophages towards a tumor-
promoting M2 phenotype [27], however the mechanisms
underlying this phenomenon are not fully understood. Because
macrophages interplay with tumor cells to produce a large amount
of CCL20 in the co-culture, and the selective depletion of
macrophages completely disrupted the release of CCL20 not only
by TAMs but also mouse CRC cells in CD11b-DTR mice, we
conclude that TAMs significantly contribute to the production of
CCL20 which drives CCR6
+ Treg-cell recruitment to the tumor
tissue. These results indicate that the tumor microenvironment
educates TAMs to switch to a specific phenotype for the
production of a wide variety of growth factors, cytokines and
chemokines that initiate and promote tumor progression [27].
Despite accumulating evidence indicates that high numbers of
TAMs in the mass of solid tumors correlate with poor cancer
prognosis [45,46], results about the role of TAMs in tumorigenesis
in CRC seem to be somewhat contradictory compared with other
cancers. In a study including 131 CRC cases, macrophages
positively influenced prognosis, although not significant in
multivariate analysis [47,48]. Furthermore, it was reported that
low infiltration of macrophages tended to occur with more
advanced CRC, and high macrophage infiltration along the tumor
front correlates with improved survival indicating that TAMs may
act as one cell population against malignant cells in patients with
CRC [49,50]. We here demonstrated for the first time that
selective ablation of TAMs resulted in an inhibition of tumor
progression, supporting a dominant protumorigenic role for
TAMs in our mouse model of CRC.
In conclusion, our data has identified a previously unrecognized
role for TAMs in contributing to the increased production of
CCL20 that recruits CCR6
+ Treg-cells and promotes CRC
development in mice. This study highlights targeting CCL20 by
down-regulating the activity of TAMs or its counter receptor
CCR6 to block memory Treg-cell recruitment may present a
promising strategy for the treatment of human CRC.
Materials and Methods
Ethics statement
Mice were kept under specific pathogen-free (SPF) conditions in
compliance with the National Institutes of Health Guide for the Care
and Use of Laboratory Animals with the approval (SYXK-2003-
0026)of the Scientific Investigation Board of Shanghai Jiao Tong
University School of Medicine, Shanghai, China. To ameliorate
any suffering of mice observed throughout these experimental
studies, mice were euthanized by CO2 inhalation. Clinical samples
were obtained from Ruijin Hospital, Shanghai Jiao Tong
University School of Medicine following protocols approved by
Shanghai Jiao Tong University School of Medicine Review Board
and following the Declaration of Helsinki Principles. PBMC or
tissues from patients with colorectal cancer were collected
simultaneously. Patients gave written informed consent. Sex and
age-matched control samples were from normal volunteers.
Mice
The C57BL/6J mice, B6.129P2-Ccr6
tm1Dgen/J (designated as
CCR62/2) mice, B6.Cg-Foxp3
tm2Tch/J (designated as FoxP3
GFP)
mice, B6.FVB-Tg (ITGAM-DTR/EGFP) 34Lan/J (designated as
CD11b-DTR) mice were purchased from the Jackson Laboratory
(Bar Harbor, ME).
Induced mouse CRC model
CRC was induced by N-methyl-N-nitrosourea (MNU) (Sigma
Chemical) and H. pylori (SS1) in 89 pathogen-free, 6-week-old
female C57BL/6J mice. In the first 10 weeks, MNU was dissolved
in distilled water at the concentration of 240 ppm and was freshly
prepared twice per week for administration in drinking water in
light-shielded bottles. The treatment MNU was performed one
week for administration and one week paused. During weeks 12 to
13, H. pylori was administrated intragastrically to the MNU treated
Figure 3. Contribution of TAMs to CCL20 production in CRC in mice. (A, B) Cryosections from mouse CRC induced by MNU and H. pylori or
mouse normal colon were stained for CCL20 (red, original magni-fication,620). Double immunostaining with anti-mouse CCL20 and F4/80 mAb was
performed on cryosections derived from mouse CRC. (C) Co-localization of CCL20 with F4/80 staining (original magnification, 620). (D) CMT93 was
transducted with GFP, and confirmed by flow cytometry. (E) Flow cytometric analysis of CCL20
+ cells three weeks after GFP
+ CMT93 cells grafting in
C57BL/6J mice. (F) mRNA levels of CCL20 for co-culture of mouse peritoneal macrophages with CMT93 cancer cells. AU, arbitrary units. (G) Protein
levels of CCL20 for co-culture of mouse peritoneal macrophages with CMT93 cancer cells. Representative data are shown which had been reproduced
in at least 2 independent experiments. * p,0.05, ** p,0.01,*** p,0.001, Student’s t test.
doi:10.1371/journal.pone.0019495.g003
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9 C.F.U/ml, 0.15 ml per
treatment, twice every other day. Apart from the treatment, the
mice were fed with normal food for rest of the time until 80 weeks.
Syngenic graft CRC model
Mouse colorectal cell line, CMT 93, was purchased from
ATCC and maintained in DMEM supplemented with 10% fetal
bovine, l-glutamine, 100 units of penicillin-G, and 100 mg/ml of
streptomycin. CMT 93 (1610
6) with or without 0.5 mg recombi-
nant mouse CCL20 in 100 ml1 6PBS were injected subcutane-
ously (s.c.) into FoxP3
GFP mice, and 0.5 mg recombinant mouse
CCL20 in 100 ml1 6PBS was injected s.c. weekly for 21 or 28
days. Control FoxP3
GFP mice were only given 100 ml1 6PBS
injection. Green fluorescence of FoxP3
GFP+ cells was monitored
using the IVIS Imaging System (Xenogen IVIS 200 System,
Xenogen Inc., Hopkinton, MA, USA) at day 28. The size of the
resulting tumors was measured with calipers weekly.
GFP transduction
Lentivirus packaging system included pGC-FU-EGFP-IRES-
Puromyciny, pMD2.G and psPAX2. DNA of the three plasmids
was extracted using Endo-free Plasmid Mini Kit (Qiagen) and then
used to transfect 293T cells using CaPO4 transfection reagents
according to the manufacturer’s instructions. 48 hours later, the
supernatant was collected and centrifuge the supernatant 10 min
at 20006g, 4uC, then filter through a 0.45-mm pore-size filter. The
flow-though is used directly for transduction of CMT93 cells.
48 hours later, puromycin was added at 5 ug/mL to select the
CMT93 cells which stable express GFP. GFP
+ CMT93 cells were
further purified by Fluorescence Activated Cell Sorter, and
expanded in the culture medium.
CMT93 and macrophages
For co-culture experiments, a transwell apparatus with 3.0 mm
pore size tissue culture treated polycarbonate membrane (24-well
plate, Lot#34409007, Costar) was applied to cancer cell/
macrophage co-cultures. Mouse peritoneal macrophages were
prepared as published before [51]. 0.5610
6 CMT93 cancer cells
were cultured with or without 0.5610
6 macrophages in 1 ml
conditioned medium and incubated for 48 hrs. Total RNA was
extracted from either CMT93 or macrophages for quantitative
RT-PCR analysis of CCL20. Culture supernatant was collected to
measure CCL20 protein levels using a Mouse CCL20/MIP-3
alpha Quantikine ELISA Kit (R&D, Cat. No.: MCC200). The
details of conditioned medium preparation has been described
previously [52].
Depletion of macrophages
DT and the inactive form of the toxin DT-mutant (DT
mu) were
purchased from EMD Chemicals. CD11b-DTR mice (5 mice for
each group) were given intraperitoneally (i.p.) either DT (25 ng/g)
or DT
mu (25 ng/g), and 48 hours later CMT 93 (1610
6) in 100 ml
16PBS were injected s.c. into CD11b-DTR mice treated with DT
or DT
mu. CD11b-DTR mice grafted with CTM93 were further
treated with DT (5 ng/g) or DT
mu (5 ng/g) i.p. every 48 hours for
14 days. The actual tumor weight was measured at autopsy.
Histological processing
Tissues from mice with CRC induced by MNU and H. pylori
were fixed in 4% paraformaldehyde solution for 24 hours, and
dehydrated, and embedded in paraffin. Paraffin-embedded 4 mm
sections of CRC were stained with hematoxylin and eosin (H&E).
Immunofluorescence staining
Frozen cryosections from mice with CRC were stained for
immunological assessment of FoxP3 expression. Rat anti-mouse
FoxP3 (eBioscience
TM, clone: FJK-16s) in conjugation with goat
anti-rat Alexa FluorH555 (invitrogen
TM), rat anti-mouse CCR6
(R&D SystemH, clone: MAB590) in conjugation with goat anti-rat
Alexa FluorH555 (invitrogen
TM), rat anti-mouse CCL20/MIP-3a
(Santa Cruz Biotechnology) in conjugation with goat anti-rat
Alexa FluorH488 or goat anti-rat Alexa FluorH555 (invitrogen
TM)
or Alexa FluorH555 (invitrogen
TM) and AlexaH555 conjugated rat
anti-mouse F4/80 (Caltag LaboratoriesH, clone: CI:A3-1) were
used. 49,6-Diamidino-2-phenylindole (DAPI) (Fluka, Seelze, Ger-
many) was employed to stain nuclei. Antibodies were diluted in a
1% antibody diluent (DakoH, Cat. No.: S3022). Isotype controls
were used for all assays. Immunostainings were analyzed with a
fluorescence microscope (Zeiss Axioskop 2 plus).
FACS analysis
The following antibodies were used for flow cytometry: PE-
conjugated anti-mouse FoxP3 staining kit (both from eBioscien-
ce
TM, San Diego, USA), APC-conjugated anti-mouse CD3
(eBioscience
TM San Diego, USA), anti-mouse CCR6 (R&D
System, clone: MAB590) in conjugation with goat anti-rat Alexa
FluorH555 (invitrogen
TM), APC-conjugated rat anti-mouse CD4
(BD Pharmingen
TM, clone: RM4-5), APC-conjugated anti-mouse
CCR6 (BioLegend, clone: 29-2L17), and Alexa488-conjugated rat
anti-mouse F4/80 (eBioscience, clone: BM8). Mouse colorectal
tumor and normal colon tissues were digested by collagenase type
I (Gibco, Grand Island,USA) and Hyaluronidase (Worthington,
Lakewood, USA) for preparation of single cell suspension. Isotype
controls were used for flow cytometric measurements.
Quantitative RT-PCR
RNA extraction and PCR were carried out as previously
described [53]. Primer sequences used were designed for murine
CCL20 (59-GACTGTTGCCTCTCGT-39,5 9-TGACTCTTAG-
GCTGAGGA-39). Cytokine and b-actin levels were calculated
relative to the amounts found in a standard sample, and
murine b-actin was employed for normalization as previously
reported [53].
Figure 4. CCL20 recruited FoxP3
+ Treg-cells to tumor mass and stimulated the growth of CRC in mice. Mouse colorectal cell line, CMT 93
(1610
6) with or without 0.5 mg mouse recombinant mouse CCL20 in 100 ml PBS were injected s.c. into FoxP3
GFP mice, and 0.5 mg recombinant mouse
CCL20 in 100 ml PBS was injected s.c. weekly for 28 days. Control FoxP3
GFP mice were only given 100 ml PBS injection. (A) Normal FoxP3
GFP mouse
was used as a technique control. (B, C) Green fluorescence of FoxP3
GFP+ cells in mice treated PBS or recombinant mouse CCL20 (white arrow) were
monitored using the IVIS Imaging System at day 28. (D) Numbers of tumor-infiltrating FoxP3
GFP+ Treg-cells derived from grafted CRC in mice treated
with PBS or recombinant mouse CCL20 were analyzed by Flow cytometry. (E) The sizes of tumors were measured with calipers at the indicated time
points for 28 days. Injection of recombinant mouse CCL20 resulted in a significant increase in tumor sizes (n=5). (F) Expression levels of CCR6 by
grafted CRC in CCR62/2 mice. (G) CMT 93 (1610
6) with or without 0.5 mg mouse recombinant mouse CCL20 in 100 ml PBS were injected s.c. into
CCR62/2 mice, and 0.5 mg recombinant mouse CCL20 in 100 ml PBS or 100 ml PBS was injected s.c. at every second day for 21 days. Tumor weight of
CRC was measured at the end of experiment. Representative data are shown which had been reproduced in 3 independent experiments. * p,0.05,
** p,0.01, Student’s t test.
doi:10.1371/journal.pone.0019495.g004
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Western blotting was performed as previously published [54].
Anti-mouse CCL20 mAb was purchased from R&D (Cat. Nr:
MAB760, clone: 114906).
Statistical analysis
Quantitative data is presented as mean values 6 standard
deviation (SD). Statistical significance was determined by means of
the two-tailed Student’s t test, or the Mann-Whitney U test in
cases of a non-gaussian distribution. Differences were considered
to be statistically significant at values of p,0.05 *, p,0.01 **,
p,0.001 ***.
Supporting Information
Figure S1 Increased numbers of FoxP3
+ Treg-cells in
peripheral blood and tumor infiltrating lymphocytes of
colorectal cancer patients. Peripheral blood derived from
either patients with CRC or healthy controls was processed for
analysis of FoxP3 expression by FACS. (A, B) Numbers of Treg
cells in peripheral blood of colorectal carcinoma patients (n=8)
and healthy individuals (n=6). (C) A significant increase of
numbers of FoxP3
+ Treg cells was found in peripheral blood of
colorectal carcinoma patients compared with healthy individuals
(p=0.008 by Student’s t Test). (D) H&E staining of colorectal
carcinoma derived from patients (original magnification,640). To
examine tumor infiltrating Treg cells in patients with colorectal
cancer, sections from paraffin-embed colorectal carcinoma tissue
(n=30) or human para-colorectal cancer tissue were subjected to
indirect immunohistochemical staining of FoxP3. (E) Expression of
FoxP3 (brown) in colorectal carcinoma (original magnification,
620). (F) Higher magnification of (E) as indicated by the rectangle.
(G) Negative expression of FoxP3 in para-colorectal cancer tissue
(original magnification, 620). (H) Higher magnification of (G)a s
indicated by the rectangle. Representative data are shown which
had been reproduced in 4 independent experiments.
(TIF)
Figure S2 Increased numbers of FoxP3
+ Treg-cells in
peripheral blood in mice with CRC. Peripheral blood
derived from either mice with CRC (n=13) or normal controls
(n=8) was processed for analysis of FoxP3 expression by FACS.
(A, B) Numbers of Treg-cells in peripheral blood of mice with
CRC and normal control mice. (E) A significant increase of
numbers of Treg-cells was observed in peripheral blood of mice
with CRC compared with controls (p=0.0219 by Student’s t Test).
Representative data are shown which had been reproduced in 3
independent experiments.
(TIF)
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